Neuroscience and Neurogenetics Research Team (ERNN), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Molecular Biology and Functional Genomics Platform, National Centre for Scientific and Technical Research, Rabat, Morocco.
Cancer Rep (Hoboken). 2024 Nov;7(11):e2158. doi: 10.1002/cnr2.2158.
Wilms tumour (WT), the second most reported childhood cancer in Morocco, is a malignant kidney tumour that affects children under 15 years old. Prognosis has improved with the adoption of multimodal treatment. However, data on WT in Morocco remain limited.
This study aims to comprehensively describe and analyse the epidemiological, clinicopathological features and treatment outcomes of WT in Moroccan patients, including treatment response and recurrence rates.
A retrospective study involved 84 children under 15 years with WT, treated according to the SIOP protocol and followed at the Paediatric Haematology and Oncology Centre at Children's hospital of Rabat, between January 2014 and February 2018. The median age of participants was 36 months, with a male/female sex ratio of 0.79. Abdominal mass was the primary concern in 55 cases (66%). Five patients (6%) had bilateral WT. Metastatic WT occurred in 21 cases (25%). Stage III was predominant in 33 cases (43%). Twenty cases (26%) had high-risk WT, and IVC tumour thrombus was observed in 12 cases (14%). WT histotype correlated significantly with both sex and tumour localisation (p values of 0.040 and 0.013, respectively). Age correlated significantly with WT extension, overall stage and SIOP histology risk grades (p values of 0.003, 0.003 and 0.045, respectively). Overall stage was statistically related to the occurrence of IVC tumour thrombus (p = 0.002). Over a 5-year span post-nephrectomy, complete remission was achieved in 63 patients (75%), partial remission in one patient (1%), while 19 patients (23%) died and one patient (1%) relapsed.
These findings are encouraging for a developing country. However, the elevated rates of Stages III and IVC thrombus in this series are still high, primarily attributed to delays in diagnosis and treatment and the limited number of paediatric haematology and oncology units at the time of the study. Nevertheless, further multicentric research is warranted to enrich Moroccan data and establish a national register for WT cases.
威尔姆斯瘤(WT)是摩洛哥报告的第二大儿童癌症,是一种影响 15 岁以下儿童的恶性肾肿瘤。采用多模式治疗后,预后有所改善。然而,摩洛哥的 WT 数据仍然有限。
本研究旨在全面描述和分析摩洛哥患者 WT 的流行病学、临床病理特征和治疗结果,包括治疗反应和复发率。
回顾性研究纳入了 2014 年 1 月至 2018 年 2 月在拉巴特儿童医院儿科血液学和肿瘤学中心接受 SIOP 方案治疗的 84 名 15 岁以下 WT 患儿。参与者的中位年龄为 36 个月,男女比例为 0.79。55 例(66%)主要表现为腹部肿块。5 例(6%)为双侧 WT。21 例(25%)发生转移性 WT。III 期为主 33 例(43%)。20 例(26%)为高危 WT,12 例(14%)可见 IVC 瘤栓。WT 组织学类型与性别和肿瘤部位显著相关(p 值分别为 0.040 和 0.013)。年龄与 WT 扩展、总分期和 SIOP 组织学危险分级显著相关(p 值分别为 0.003、0.003 和 0.045)。总分期与 IVC 瘤栓的发生有统计学关系(p=0.002)。肾切除术后 5 年内,63 例(75%)患者达到完全缓解,1 例(1%)患者部分缓解,19 例(23%)死亡,1 例(1%)复发。
这些发现对发展中国家来说是令人鼓舞的。然而,本研究中 III 期和 IVC 血栓的发生率仍然较高,主要归因于诊断和治疗的延迟,以及研究时儿科血液学和肿瘤学单位的数量有限。然而,需要进一步的多中心研究来丰富摩洛哥的数据并建立 WT 病例的国家登记处。